Dr. Ramalingam on Pemetrexed and Bevacizumab as Maintenance Therapy for Advanced NSCLC

Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.

Cancer Network spoke with Suresh S. Ramalingam, MD, professor of hematology/oncology and the deputy director of Winship Cancer Institute, Emory University, about the results of the ECOG-ACRIN 5508 trial (abstract 9002). The study focused on pemetrexed, bevacizumab, or a combination of both as maintenance therapy for advanced non-squamous NSCLC, and the findings were presented at ASCO 2019.